Eagle Pharmaceuticals (EGRX) Announces Strong Preclinical Data on Ryanodex as MDMA-Related Hyperthermia Treatment
- Futures flat ahead of Easter break, Wall St set for sharp Q1 gains
- Home Depot agrees to buy SRS Distribution, sees TAM expanding to $1 trillion
- Yen on intervention watch; Asia shares creep higher
- Dollar gains as inflation data looms; yen on intervention watch
- Piper Sandler: Stock rally likely to continue on rising recession risks
- Discover Financial Services (DFS) Announces CEO Resignation
- Timken (TKR) Appoints Tarak Mehta as New CEO
- Crude Inventory Increases 3.2 Million Barrels
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- Many senior Amazon employees won't get cash raises this year - Fortune
Eagle Pharmaceuticals Announces Positive Initial Results of Animal Study Exploring Use of Ryanodex in MDMA (Ecstasy) Induced Hyperthermia Conducted at the National Institutes of Health
October 31, 2016 7:00 AM EDT-- Ryanodex-treated animals experienced a greater decrease in brain temperature from peak temperature values, compared to animals in the control group
- Brain temperature in Ryanodex-treated animals returned to baseline --
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) (Eagle or the Company) today announced initial results from the preclinical study conducted by Eagle at the National Institute on Drug Abuse (NIDA)/National Institutes of Health (NIH) exploring the use of Ryanodex® in the treatment of hyperthermia related to MDMA (Ecstasy) intoxication. The study was conducted in the summer of 2016... More